Are you suffering from C. diff ?

Clinical Study Now Enrolling
Sierra Clinical Research
using Fecal Transplant Therapy.

Options now available for patients that do not qualify for other C. diff  studies

Fecal Transplant Therapy Clinical Trial Now Enrolling
Fecal Transplant Therapy Clinical Trial Now Enrolling

Join the Battle to Defeat C. diff  Infection

PUNCH CD3-OLS is a clinical study to evaluate the safety and tolerability of Rebiotix RBX2660 for the prevention of recurrent Clostridium difficile infection (C. diff or CDI). With this study option, many more people that suffer from recurrent C. diff  may now qualify for study participation.

Study patients receive expert medical care and specialized attention from the study team. The cost of the study drug, study-related tests, as well as study follow-up calls and visits will be covered by the study sponsor, Rebiotix.

If you or someone you know has a C. diff  infection, contact Maya Pudi, MBS, CCRC at Sierra Clinical Research to learn more. With your help, we can put a stop to this deadly disease.

Call or E-mail to Find Out if You May Participate
Name: Maya Pudi, MBS, CCRC
Phone: 702-374-0374

To learn more about participating in the PUNCH CD3-OLS clinical study

The PUNCH CD3-OLS clinical study is open for adults with recurrent C. diff  infection that is only controlled by taking antibiotics. To speak with the clinical research coordinator at a study site in your area, please provide the following information:

    I am currently or have recently been treated for a C. diff infection and am interested in participating in a study for recurrent C. diff in my area.I am contacting you on behalf of a friend or family member that is currently or has recently been treated for a C. diff infection.I am interested in learning more about C. diff infections.


    How to Participate

    Patients that may qualify for the PUNCH CD3-OLS study:

    • 18 years and older
    • Have experienced more than one C. diff  infection
    • Currently taking or just prescribed antibiotics to control C. diff  diarrhea
    • Willing and able to meet all study requirements

    The clinical study team will review the complete requirements and determine if you are eligible to participate in the clinical study. Personal information you share will be kept confidential.

    If it is determined you may be a candidate for the PUNCH CD3-OLS clinical study, you will:

    • Be asked to visit the clinical site if you are interested in participating
    • Receive detailed information regarding the clinical study, the risks and benefits of participating, and your responsibilities as a participant
    • Have time for your questions to be answered, and talk about the study with others (family and friends)
    • If you are confirmed to be a candidate and decide to participate, you may be compensated for completing required study visits and phone calls

    To see if you may qualify for the PUNCH CD3-OLS clinical study

    Fecal Transplant Therapy Clinical Trial Now Enrolling
    Fecal Transplant Therapy Clinical Trial Now Enrolling

    What is RBX2660 and how does it prevent C. diff  infection?

    RBX2660 (microbiota suspension) is an investigational new drug that may prevent recurrent C. diff  infection from returning. It is a biologic drug product prepared from live intestinal microbes, which are tiny living cells that can’t be seen without a microscope. The study drug is delivered in a single simple enema, unlike Fecal Microbiota Transplant (FMT) by colonoscopy or taking many pills.

    Everyone has "good" and "bad" microbes that live in their intestines. In healthy people, the good microbes keep the bad microbes in balance. There is scientific evidence that people who experience repeated episodes of C. diff  may have an imbalance in their intestines that allows the "bad" microbes to grow more easily and overtake the good microbes, which causes severe diarrhea and other symptoms, and can be life-threatening.1

    Some research studies have shown that putting a mix of good microbes into the intestines of someone infected with C. diff  may relieve or stop C. diff .2,3 The purpose of this study is to learn about the safety of RBX2660, and determine whether it is effective at preventing recurrent C. diff  infection.

    Want More Information About the Study?

    Further information is available:


    1. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile Infection: new developments in epidemiology and pathogenesis.Nat Rev Microbiol. 2009;7(7):526-536.
    2. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal Infusion of donor feces for Recurrent Clostridium difficle. N Eng J Med 2013; 386(5):407-415.
    3. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for Recurrent Clostridium difficile infection. Clin Infect Dis. 2011 Nov;53(10):994-1002.


    Rebiotix Inc.
    2660 Patton Road
    Roseville, MN 55113